Is Pomalidomide included in medical insurance?

Pomalidomide, independently developed in China, has been launched in China and is covered by medical insurance. It is suitable for adult multiple myeloma patients who have received at least two treatments in the past (including lenalidomide and a proteasome inhibitor) and whose disease has progressed during the last treatment or within 60 days after the end of treatment. Patients who are not eligible may need to purchase it at their own expense.

Pomalidomide represents a new drug for the treatment of refractory/relapsed multiple myeloma, with direct effects on myeloma cells and modulation of the bone marrow microenvironment translating into clinical efficacy. The results of the phase III trial provide a theoretical basis for its combination with dexamethasone in patients who have failed multiple lines of treatment, including bortezomib and lenalidomide-based regimens. Toxicity is manageable and there are benefits to oral administration. Combination with alkylating agents, proteasome inhibitors, or other novel compounds may further improve response rates.

Domestic Pomalidomide The price of each box may be around RMB 4,000, and this drug may be sold in domestic pharmacies or hospitals. The price of each box of the Turkish version listed overseas may be around 15,000 yuan (the price may fluctuate due to exchange rates), which is relatively expensive. There are also cheaper generic drugs produced in other countries overseas. The price of each box produced by a Lao pharmaceutical factory may be around a few hundred yuan (the price may fluctuate due to the exchange rate). The ingredients of foreign generic drugs, domestically produced drugs and foreign original drugs are basically the same. For more drug information and specific prices, please consult a medical consultant. Purchase overseas drugs must be purchased through formal channels.